Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma
20.10.2026 14:00:00 CEST | Business Wire | Press Release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors.
Debiopharm’s planned activities at ESMO 2026 include:
- Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma.
- Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating single-agent zedoresertib in advanced solid tumors, including uterine serous carcinoma and Cyclin E1-overexpressing high-grade ovarian cancer.
- Meet-the-Expert Event (MYTHIC Study): An invitation-only session alongside the congress during which leading international oncology experts will discuss emerging data from the MYTHIC clinical trial (Debio 0123-106 / NCT04855656), dual WEE1/PKMYT1 checkpoint inhibition, and precision biomarker selection.
“The data to be presented at ESMO 2026 reinforce our belief that zedoresertib has the potential to become a breakthrough therapy in oncology in combination with key agents across multiple tumor types,” expressed Esteban Rodrigo Imedio, Executive Medical Director, Oncology at Debiopharm. “From establishing single-agent disease control in solid tumors and confirming blood-brain barrier penetrance in glioblastoma to advancing dual WEE1/PKMYT1 targeting in the MYTHIC trial, we are committed to unlocking the benefits of synthetic lethality for patients battling hard-to-treat cancers.”
Clinical Progression: Monotherapy, Glioblastoma, and Combination Strategies
Zedoresertib (Debio 0123) is a potent, oral, brain-penetrant, and highly selective WEE1 kinase inhibitor. In the monotherapy expansion study (Debio 0123-102), continuous daily administration of zedoresertib at the recommended Phase 2 dose demonstrated a manageable safety profile alongside evidence of target engagement and signals of activity in heavily pretreated solid tumors, particularly uterine serous carcinoma and ovarian cancer. In parallel, the Debio 0123-GBM-105 clinical trial in recurrent glioblastoma confirmed early signals of antitumor activity, central nervous system penetration and a manageable safety profile in combination with temozolomide, supporting ongoing evaluation in randomized cohorts.
Supported by this favorable tolerability profile and single-agent foundation, Debiopharm has expanded zedoresertib’s clinical evaluation into rational combination regimens. The ongoing MYTHIC trial evaluates zedoresertib in combination with lunresertib, a first-in-class, selective oral PKMYT1 inhibitor, in patients with advanced solid tumors, particularly ovarian cancer.
Therapeutic Rationale: Exploiting Synthetic Lethality in DDR
The scientific rationale underlying Debiopharm’s DDR pipeline focuses on targeted cell-cycle checkpoint disruption. Combining WEE1 and PKMYT1 inhibition creates a dual-checkpoint blockade within the G2/M transition, preventing cancer cells from repairing DNA damage and inducing mitotic catastrophe. Early clinical data from the MYTHIC study indicate promising signs of synthetic lethality and tumor regression in biomarker-selected populations, notably patients harboring CCNE1 amplification as well as FBXW7 or PPP2R1A alterations. Clinical development continues to refine combination dosing and biomarker selection in the MYTHIC trial for solid tumors, while advancing randomized expansion cohorts to evaluate zedoresertib with temozolomide in glioblastoma.
ESMO 2026 Presentation Details
Session Type | Date & Time | Presentation Title / Location | Presenter / Host |
Rapid Oral
| Friday, Oct 23 14:07 – 14:12 | 699RO: Dose Escalation of Debio 0123 Plus Temozolomide in Recurrent/Progressive Glioblastoma |
Dr. Maria Vieito
|
Poster Presentation
|
Monday, Oct 26
| 1273P (Abstract #3519): Expansion data disclosure of the Phase 1 trial of WEE1 inhibitor zedoresertib |
Dr. Maria M. Rubinstein
|
Meet-the-Expert
|
Saturday, Oct 24
| Beyond Biomarkers: Advancing DDR-Targeted Therapy in Ovarian Cancer and Solid Tumors |
Debiopharm
|
ABOUT DNA DAMAGE REPAIR (DDR)
When cells have damaged DNA, they must undergo a repair process known as DDR to survive. Cancer cells rely heavily on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, ultimately activating a programmed cell death process. DDR inhibitors such as zedoresertib (Debio 0123), Debiopharm’s WEE1 inhibitor, are currently being investigated in clinical and preclinical studies.
ABOUT PKMYT1 INHIBITION
Lunresertib (Debio2513) is a first-in-class, oral PKMYT1 inhibitor designed to exploit specific genetic vulnerabilities in solid tumors, such as CCNE1 amplification. PKMYT1 acts as a key regulator at the G2/M checkpoint, and its inhibition reduces CDK1 activity, thereby preventing cancer cells from properly repairing DNA damage and forcing them into programmed cell death. As the most advanced PKMYT1 inhibitor in clinical development, lunresertib has shown encouraging proof-of-concept results both as monotherapy and in combination therapies within the ongoing MYTHIC trial.
DEBIOPHARM’S COMMITMENT TO CANCER PATIENTS
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high potential assets and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.
Learn more about:
- The Debio 0123-GBM-105 trial: Glioblastoma - Debiopharm - Patients
- The MYTHIC trial: Solid Tumors- Debiopharm- Patients
Visit us at https://www.debiopharm.com/our-expertise/ddr/
Follow us: https://www.linkedin.com/company/debiopharminternational/
View source version on businesswire.com: https://www.businesswire.com/news/home/20261020575136/en/
Contacts
Debiopharm Contact
Dawn Bonine
Head of Communications
Dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IntouchCX Recognized for Operations led AI and End to End CX Transformation by HFS Research6.11.2026 15:00:00 CET | Press Release
IntouchCX a global leader in AI-powered customer experience (CX) management, trust and safety, digital engagement, and back-office operations, has been positioned in the Horizon 2 end-to-end experience transformation, in the HFS Horizons Customer Experience Services 2026 report for its operations led approach to AI adoption and its model connecting advisory with delivery, from strategy through frontline executions. HFS Research evaluates customer experience service providers based on their capabilities, innovation, and potential to deliver value. The 2026 report examines how providers are helping businesses adopt AI, improve customer experiences and strengthen operations. “AI transformation delivers the greatest value when strategy, technology, and operations work together,” said Brent Stevenson, Chief Experience Officer at IntouchCX. “Our approach and expertise goes beyond technology. We identify business challenges and build the right solutions by connecting the dots between data, wo
The Estée Lauder Companies Unveils Mastering Skin Longevity, a Breakthrough Scientific Innovation Platform Advancing the Next Era of Skin Science6.11.2026 15:00:00 CET | Press Release
At the China International Import Expo (CIIE), The Estée Lauder Companies Inc. (NYSE: EL) today unveiled Mastering Skin Longevity, a breakthrough scientific innovation platform designed to advance the next era of skin science and transformative product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106776704/en/ The Estée Lauder Companies' Skin Longevity Clock serves as the visual representation for the Mastering Skin Longevity scientific innovation platform. Moving beyond the study of individual Hallmarks of Aging, the platform focuses further upstream on the Master Regulators of Skin Longevity. These interconnected biological pathways and proteins influence multiple hallmarks at once. By deepening understanding of these systems and how they help support skin’s ability to repair, adapt and regenerate, Mastering Skin Longevity will guide the Company’s discovery across ingredients, technologies, formulations an
Experian Named a Leader in 2026 IDC MarketScape for Worldwide Decision Intelligence Platforms6.11.2026 15:00:00 CET | Press Release
Experian today announced it has been named a Leader in the IDC MarketScape: Worldwide Decision Intelligence Platforms 2026 Vendor Assessment (Doc #US54118426, September 2026), which evaluates providers helping organizations design, engineer and orchestrate increasingly complex decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106302874/en/ IDC MarketScape positions Experian as a Leader in its 2026 vendor assessment of worldwide decision intelligence platform providers. “As organizations embed AI into more consequential decisions, the combination of trusted data, advanced analytics and strong governance becomes increasingly important,” said Keith Little, President of Experian Software Solutions. “Experian brings those capabilities together with decisioning, fraud and identity to help organizations make better decisions with greater speed and confidence.” The Experian Ascend Platform provides a unified analytics and
Midas Atlantic Partners, i partnerskap med The Najafi Companies, har ingått ett putoptionsavtal med Sylvamo avseende ett potentiellt förvärv av Sylvamos europeiska verksamhet6.11.2026 12:05:00 CET | Pressmeddelande
Midas Atlantic Partners (”Midas Atlantic”), i partnerskap med The Najafi Companies, har ingått ett putoptionsavtal med Sylvamo Corporation (”Sylvamo”) avseende ett potentiellt förvärv av Sylvamos europeiska verksamhet (”Verksamheten”). Transaktionen omfattar Sylvamos bruk för obestruket träfritt papper i Saillat och Nymölla samt bolagets skogsverksamhet och stödjande affärsverksamhet i hela Europa. Transaktionen förväntas slutföras under första kvartalet 2027, efter att erforderliga samrådsprocesser har genomförts och myndighetsgodkännanden har erhållits. Verksamheten är en ledande europeisk tillverkare av obestruket träfritt papper för kontorsbruk och kommersiellt tryck. Produktportföljen omfattar kontorspapper i arkformat, som säljs under egna varumärken såsom REY och Multicopy samt för stora OEM-kunder och kunder inom kontorsmaterial, och pappersrullar för kommersiella tryckerier och konverterare. Verksamheten har sitt huvudkontor i Belgien och två storskaliga, vertikalt integrerade
Midas Atlantic Partners, in Partnership With the Najafi Companies, Has Entered Into a Put Option Agreement With Sylvamo Relating to the Potential Acquisition of Its European Operations6.11.2026 12:04:00 CET | Press Release
Midas Atlantic Partners (“Midas Atlantic”), in partnership with The Najafi Companies, has signed a put option agreement with Sylvamo Corporation (“Sylvamo”) relating to the potential acquisition of its European operations (the “Business”). The transaction comprises Sylvamo’s uncoated freesheet paper mills in Saillat and Nymölla, as well as its forestry and supporting business operations across Europe. Closing is expected in the first quarter of 2027, once the required consultation processes are completed and regulatory approvals are obtained. The Business is a leading European producer of uncoated woodfree (UWF) paper for office and commercial printing. Its product portfolio spans cut-size office paper, sold under its own brands such as REY and Multicopy as well as on behalf of major OEM and office supplies customers, and paper reels for commercial printers and converters. Headquartered in Belgium, with two large-scale, vertically integrated pulp and paper mills, it serves a longstandi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom